Altimmune announced positive results from the IMPACT Phase 2b trial of pemvidutide in MASH patients at 48 weeks.
Significant improvements in key non-invasive markers of fibrosis observed across treatment arms.
Favorable tolerability profile maintained at 48 weeks.
Improvements in Non-Invasive Markers
Statistically significant reductions in primary markers of fibrosis and hepatic inflammation.
Weight Loss
Pemvidutide doses achieved weight loss without plateauing, showing continued effectiveness.
Tolerability Profile
Low discontinuation rate due to adverse events, indicating favorable tolerability of pemvidutide.
- Pemvidutide showed continued antifibrotic activity with reductions in key non-invasive tests at 48 weeks.
- Positive outcomes in liver health measures and hepatic inflammation markers.
- Participants on pemvidutide demonstrated significant weight loss without plateauing.
The success of pemvidutide in the IMPACT trial reinforces its potential as an effective treatment for MASH patients. The notable improvements in non-invasive markers and weight loss outcomes are promising for future clinical evaluations.